216 related articles for article (PubMed ID: 10523073)
41. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Whitehead VM; Shuster JJ; Vuchich MJ; Mahoney DH; Lauer SJ; Payment C; Koch PA; Cooley LD; Look AT; Pullen DJ; Camitta B
Leukemia; 2005 Apr; 19(4):533-6. PubMed ID: 15716987
[TBL] [Abstract][Full Text] [Related]
42. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia.
Kinoshita A; Kurosawa Y; Kondoh K; Suzuki T; Manabe A; Inukai T; Sugita K; Nakazawa S
Cancer Chemother Pharmacol; 2003 Mar; 51(3):256-60. PubMed ID: 12655445
[TBL] [Abstract][Full Text] [Related]
43. Association between a microRNA binding site polymorphism in SLCO1A2 and the risk of delayed methotrexate elimination in Chinese children with acute lymphoblastic leukemia.
Wang SM; Zeng WX; Wu WS; Sun LL; Yan D
Leuk Res; 2018 Feb; 65():61-66. PubMed ID: 29306656
[TBL] [Abstract][Full Text] [Related]
44. 6-mercaptopurine: efficacy and bone marrow toxicity in childhood acute lymphoblastic leukemia. Association with low (thio)purine enzyme activity.
De Abreu RA; Lambooy LH; Ahment K; Brouwer C; Keizer-Garritsen JJ; Bokkerink JP; Trijbels FJ
Adv Exp Med Biol; 2000; 486():271-5. PubMed ID: 11783498
[No Abstract] [Full Text] [Related]
45. Folic acid supplements in vitamin tablets: a determinant of hematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia.
Schrøder H; Clausen N; Ostergård E; Pressler T
Pediatr Hematol Oncol; 1986; 3(3):241-7. PubMed ID: 3153236
[TBL] [Abstract][Full Text] [Related]
46. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
[TBL] [Abstract][Full Text] [Related]
47. Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.
Estlin EJ; Lowis SP; Hall AG
Br J Haematol; 2000 Jul; 110(1):29-40. PubMed ID: 10930977
[No Abstract] [Full Text] [Related]
48. Continuing therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of methotrexate, 6-mercaptopurine and 6-thioguanine.
Estlin EJ
Cancer Treat Rev; 2001 Dec; 27(6):351-63. PubMed ID: 11908928
[TBL] [Abstract][Full Text] [Related]
49. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
[TBL] [Abstract][Full Text] [Related]
50. Allopurinol Use During Maintenance Therapy for Acute Lymphoblastic Leukemia Avoids Mercaptopurine-related Hepatotoxicity.
Giamanco NM; Cunningham BS; Klein LS; Parekh DS; Warwick AB; Lieuw K
J Pediatr Hematol Oncol; 2016 Mar; 38(2):147-51. PubMed ID: 26808368
[TBL] [Abstract][Full Text] [Related]
51. [Biochemical and clinico-pharmacological aspects of antimetabolites in the treatment of leukemia].
Bökkerink JP; de Abreu RA; Lippens RJ; Schouten TJ; de Vaan GA
Tijdschr Kindergeneeskd; 1988 Apr; 56(2):55-60. PubMed ID: 3287684
[TBL] [Abstract][Full Text] [Related]
52. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6-mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia.
Tanaka Y; Manabe A; Fukushima H; Suzuki R; Nakadate H; Kondoh K; Nakamura K; Koh K; Fukushima T; Tsuchida M; Koike K; Kiyokawa N; Noguchi E; Sumazaki R; Komiyama T
Pharmacogenomics J; 2015 Aug; 15(4):380-4. PubMed ID: 25403995
[TBL] [Abstract][Full Text] [Related]
53. Thiopurine treatment in childhood leukemia. Metabolic aspects and sensitivity.
De Abreu RA; Bokkerink JP; Keuzenkamp-Jansen CW; Stet EH; Trijbels JF
Adv Exp Med Biol; 1998; 431():687-92. PubMed ID: 9598153
[No Abstract] [Full Text] [Related]
54. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.
Zaza G; Cheok M; Yang W; Panetta JC; Pui CH; Relling MV; Evans WE
Blood; 2005 Sep; 106(5):1778-85. PubMed ID: 15905191
[TBL] [Abstract][Full Text] [Related]
55. Detection and identification of 6-methylmercapto-8-hydoxypurine, a major metabolite of 6-mercaptopurine, in plasma during intravenous administration.
Keuzenkamp-Jansen CW; van Baal JM; De Abreu RA; de Jong JG; Zuiderent R; Trijbels JM
Clin Chem; 1996 Mar; 42(3):380-6. PubMed ID: 8598099
[TBL] [Abstract][Full Text] [Related]
56. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
57. [Long-term results of 2 therapeutic protocols in children with acute lymphoblastic leukemia of usual risk. Experience at the 20th of November National Medical Center].
López-Hernández MA; de Diego Flores-Chapa J; Borbolla-Escoboza JR; Trueba-Christy E; Carrillo-Rosales T; González-Avante M
Gac Med Mex; 1998; 134(2):145-51. PubMed ID: 9618993
[TBL] [Abstract][Full Text] [Related]
58. Thiopurine methyl transferase: activity and genotyping in patients with acute lymphoblastic leukemia.
Brouwer C; Keizer-Garritsen JJ; Lambooy LH; Ament K; Ter Riet PG; De Abreu RA; Bökkerink JP; Van Wering ER; Van Der Does-Van Den Berg A; Veerman AJ; Trijbels JP
Adv Exp Med Biol; 2000; 486():327-31. PubMed ID: 11783509
[No Abstract] [Full Text] [Related]
59. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
Nersting J; Nielsen SN; Grell K; Paerregaard M; Abrahamsson J; Lund B; Jonsson OG; Pruunsild K; Vaitkeviciene G; Kanerva J; Schmiegelow K;
Cancer Chemother Pharmacol; 2019 Jan; 83(1):53-60. PubMed ID: 30324220
[TBL] [Abstract][Full Text] [Related]
60. Sequence-, time- and dose-dependent synergism of methotrexate and 6-mercaptopurine in malignant human T-lymphoblasts.
Bökkerink JP; Bakker MA; Hulscher TW; De Abreu RR; Schretlen ED; van Laarhoven JP; De Bruyn CH
Biochem Pharmacol; 1986 Oct; 35(20):3549-55. PubMed ID: 2429667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
